Ozempic may reduce epilepsy risk in type 2 diabetes patients

ndtv.com

A new study suggests Ozempic and similar GLP-1 drugs may reduce epilepsy risk in type 2 diabetes patients. Researchers analyzed a U.S. health database, finding a 16% lower epilepsy risk in GLP-1 users compared to those on DPP-4 inhibitors, with semaglutide showing the strongest effect. While promising, further randomized trials are needed to confirm these neurological benefits, as diabetes itself increases epilepsy risk.


With a significance score of 5.3, this news ranks in the top 1% of today's 31380 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers: